D D Ho

Summary

Affiliation: Aaron Diamond AIDS Research Center
Country: USA

Publications

  1. ncbi request reprint Multiple-site DNA vaccination enhances immune responses in mice
    David F Gardiner
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Vaccine 24:287-92. 2006
  2. ncbi request reprint Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
    Lei Ba
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, New York, NY 10016, USA
    Appl Microbiol Biotechnol 76:1131-6. 2007
  3. pmc Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy
    H Mohri
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Exp Med 194:1277-87. 2001
  4. pmc A shot in the arm for AIDS vaccine research
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA
    PLoS Med 2:e36. 2005
  5. ncbi request reprint The HIV-1 vaccine race
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Cell 110:135-8. 2002
  6. doi request reprint HIV-1 at 25
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 133:561-5. 2008
  7. pmc Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection
    L A Chakrabarti
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 74:1209-23. 2000
  8. pmc DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques
    S Cherpelis
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10021-6399, USA
    J Virol 75:1547-50. 2001
  9. pmc Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    J M Binley
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2799-809. 1997
  10. ncbi request reprint The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
    M Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    J Infect Dis 179:527-37. 1999

Collaborators

Detail Information

Publications74

  1. ncbi request reprint Multiple-site DNA vaccination enhances immune responses in mice
    David F Gardiner
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Vaccine 24:287-92. 2006
    ..Enhanced systemic responses correlate directly with recruitment of antigen-specific CD8+ T-cells in the regional lymph nodes. These results have implications for DNA vaccination in humans...
  2. ncbi request reprint Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
    Lei Ba
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, New York, NY 10016, USA
    Appl Microbiol Biotechnol 76:1131-6. 2007
    ..Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection...
  3. pmc Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy
    H Mohri
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Exp Med 194:1277-87. 2001
    ..Taken together, these new findings strongly indicate that CD4(+) lymphocyte depletion seen in AIDS is primarily a consequence of increased cellular destruction, not decreased cellular production...
  4. pmc A shot in the arm for AIDS vaccine research
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA
    PLoS Med 2:e36. 2005
  5. ncbi request reprint The HIV-1 vaccine race
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Cell 110:135-8. 2002
    ..Significant technological advances are also required to overcome the unique obstacles posed by HIV-1. Some of the challenges we face in this endeavor are discussed here...
  6. doi request reprint HIV-1 at 25
    David D Ho
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Cell 133:561-5. 2008
    ..Today, 33 million persons are living with infection by the human immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, while another 25 million have already died of this disease...
  7. pmc Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection
    L A Chakrabarti
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 74:1209-23. 2000
    ..Normal T-cell turnover in SIV-infected mangabeys provides an explanation for the long-term maintenance of a functional immune system in these hosts...
  8. pmc DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques
    S Cherpelis
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10021-6399, USA
    J Virol 75:1547-50. 2001
    ..Compared to unvaccinated animals, the vaccinated macaques had lower peak viremia levels, rapidly cleared plasma virus, and showed delayed seroconversion...
  9. pmc Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    J M Binley
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2799-809. 1997
    ....
  10. ncbi request reprint The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
    M Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    J Infect Dis 179:527-37. 1999
    ..In addition, given the reduction in levels of virus-specific immune responses, it would seem prudent to consider enhancing these responses using vaccine strategies prior to the withdrawal of antiviral therapy...
  11. pmc Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
    R I Connor
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:7501-9. 1998
    ....
  12. pmc Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1
    L Zhang
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:9307-12. 1998
    ....
  13. ncbi request reprint DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques
    S Cherpelis
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10021-6399, USA
    Immunol Lett 79:47-55. 2001
    ....
  14. ncbi request reprint Age-dependent changes in T cell homeostasis and SIV load in sooty mangabeys
    L A Chakrabarti
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Med Primatol 29:158-65. 2000
    ..Thus, the number of susceptible target cells may be a limiting factor in natural SIV infection...
  15. pmc Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry
    Z Chen
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2705-14. 1997
    ..These findings indicated that, in addition to CCR5, SIV can use one or more unknown coreceptors that are expressed on human PBMCs and CEMx174 cells...
  16. pmc Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy
    Xia Jin
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 76:2206-16. 2002
    ..In summary, vaccination with vCP1452 and recombinant gp160 appears safe and immunogenic in newly HIV-1-infected patients on HAART...
  17. ncbi request reprint Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy
    D F Nixon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Immunol Lett 66:219-28. 1999
    ..This latter population may represent persisting HIV specific memory CTL...
  18. pmc Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism
    M Pope
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA
    J Virol 71:8001-7. 1997
    ..Our findings do not support the conclusion that subtype E strains have a preferential tropism for DCs, suggesting that other explanations for the rapid heterosexual spread of subtype E strains in Asia should be considered...
  19. doi request reprint Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'
    Zhiwei Chen
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 47:412-21. 2008
    ..ADMVA has since been advanced into clinical trials. A phase 1 study has been completed, and a prime-boost with ADVAX (see accompanying article) is now underway...
  20. pmc Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain
    Christopher E Yi
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 79:11638-46. 2005
    ..Our data have implications for the rational design of vaccine and antiviral agents as well as for understanding viral tropism...
  21. pmc Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus
    Li Liu
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Virol 81:4694-700. 2007
    ....
  22. pmc In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5
    L Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:5035-45. 1998
    ..These findings may be helpful in understanding certain aspects of HIV and SIV pathogenesis and transmission...
  23. ncbi request reprint Determining the relative efficacy of highly active antiretroviral therapy
    Michael Louie
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
    J Infect Dis 187:896-900. 2003
    ..Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted...
  24. doi request reprint Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide
    Yaoxing Huang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Vaccine 26:1807-16. 2008
    ..Since both mice and humans share the CD1d molecule, this information may aid in designing more effective DNA vaccines and vaccine adjuvants against HIV-1...
  25. ncbi request reprint Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development
    David Franco
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Vaccine 28:5676-85. 2010
    ..These results suggest that YF17D warrants serious consideration as a live-attenuated vector for HIV-1 vaccine development...
  26. ncbi request reprint CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV)
    Zhiwei Chen
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Acquir Immune Defic Syndr 30:133-45. 2002
    ..Our data indicate that the R5-mediated CD4+ lymphocytopenia in the gut is likely independent of HIV-1 genotypes and of the function of vpu at the acute phase of viral infection...
  27. pmc Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 69:6609-17. 1995
    ..Furthermore, if the three MAbs and CD4-IgG2 produce clinical benefit in immunotherapeutic trials in the United States or Europe, they may also do so elsewhere in the world...
  28. pmc Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo
    L Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2555-61. 1997
    ..e., that transmission does not reset the evolutionary clock...
  29. ncbi request reprint HIV-1 dynamics in vivo: implications for therapy
    Viviana Simon
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nat Rev Microbiol 1:181-90. 2003
    ..We also discuss the obstacles that result from the ability of HIV-1 to remain dormant for a prolonged period of time in a subset of long-lived cells, despite an apparently effective antiretroviral treatment...
  30. ncbi request reprint Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
    ..Additional studies are needed to understand the host- and pathogen-related determinants of incomplete pharmacologic control of HIV-1 replication...
  31. doi request reprint Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant
    Yaoxing Huang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 47:403-11. 2008
    ..A phase 1 clinical trial of this product has been successfully completed, and its use in prime-boost studies is now underway...
  32. pmc Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients
    H Mohri
    Aaron Diamond AIDS Research Center, Department of Medicine and Microbiology, New York University School of Medicine, NY 10016
    Proc Natl Acad Sci U S A 90:25-9. 1993
    ..These findings serve to emphasize the magnitude of the AZT-resistance problem in patients on drug treatment...
  33. ncbi request reprint Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    Lancet 365:1031-8. 2005
    ..Here, we describe a patient in whom these two factors arose concomitantly and assess the effects...
  34. pmc Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
    Zhiwei Chen
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Virol 79:2678-88. 2005
    ..In addition, ADS-MVA induced potent immune responses which very likely protected Chinese rhesus monkeys from pathogenic SARS-CoV challenge...
  35. pmc Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection
    Linqi Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 76:9465-73. 2002
    ....
  36. pmc Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients
    Ruijiang Song
    Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY, USA
    J Virol 84:6935-42. 2010
    ....
  37. pmc A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Virol 77:5037-8. 2003
    ..7 day, and the generation time of HIV-1 in vivo, approximately 2 days, confirming the dynamic nature of HIV-1 replication...
  38. pmc Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8816. 2010
    ..Sequences were derived from a prevalent circulating HIV-1 recombinant form in Yunnan, China, an area of high HIV incidence. The objective was to evaluate the safety and immunogenicity of ADMVA in human volunteers...
  39. pmc Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine
    Sandhya Vasan
    Aaron Diamond AIDS Research Center, New York, New York, United States of America
    PLoS ONE 5:e8617. 2010
    ..Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers...
  40. ncbi request reprint Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor
    Linqi Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Science 298:995-1000. 2002
    ..Taken together, our results indicate that alpha-defensin 1, 2, and 3 collectively account for much of the anti-HIV-1 activity of CAF that is not attributable to beta-chemokines...
  41. ncbi request reprint Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
    ....
  42. pmc Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china
    Linqi Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    J Virol 78:13591-9. 2004
    ....
  43. pmc HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    Lancet 368:489-504. 2006
    ..This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1...
  44. pmc Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 467:591-5. 2010
    ..Despite the low affinity of the polyreactive combining site, heteroligation demonstrably increases the apparent affinity of polyreactive antibodies to HIV...
  45. ncbi request reprint The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy
    Jerome K Percus
    Courant Institute of Mathematical Sciences, New York University, New York, NY 10012, USA
    Bull Math Biol 65:263-77. 2003
    ....
  46. pmc Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner
    J A McKeating
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Ave, New York, NY 10021, USA
    J Virol 78:8496-505. 2004
    ..Our current model of HCV infection suggests that CD81, together with additional unknown liver specific receptor(s), mediate the virus-cell entry process...
  47. pmc Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques
    Hannah Yuan Chen
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 104:19079-84. 2007
    ....
  48. pmc Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant
    Xiangming Li
    Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 107:13010-5. 2010
    ..Through this rigorous and iterative screening process, we have identified a lead candidate glycolipid, 7DW8-5, that exhibits a superior adjuvant effect than alpha-GalCer on HIV and malaria vaccines in mice...
  49. ncbi request reprint HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism
    L Zhang
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 13:1357-66. 1997
    ..Therefore, the uneven worldwide distribution of HIV-1 subtypes is more likely the result of stochastic dissemination...
  50. pmc Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody
    N Sullivan
    Division of Human Retrovirology, Dana Farber Cancer Institute, New York, New York
    J Virol 67:3674-9. 1993
    ....
  51. ncbi request reprint Isolation and quantitation of HIV in peripheral blood
    R A Koup
    Aaron Diamond AIDS Research Center and New York University School of Medicine, New York, New York, USA
    Curr Protoc Immunol . 2001
    ..A consequence of HIV infection is the depletion of CD4(+) target cells, evidenced by syncytia formation or single-cell death; two support protocols detail the evaluation of these cytopathic effects...
  52. pmc A recoding method to improve the humoral immune response to an HIV DNA vaccine
    Yaoxing Huang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, United States of America
    PLoS ONE 3:e3214. 2008
    ..Our sequence, which has the motifs removed, induces a five-fold increase in gag antibody response compared to the codon optimized vaccine...
  53. ncbi request reprint Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus
    Sarah Tuttleton Arron
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Eur J Immunol 35:46-55. 2005
    ..We therefore conclude that peripheral destructive processes, rather than a loss of thymic output, appear to be the main causes of T cell depletion in SIV infection...
  54. pmc The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys
    Linqi Zhang
    Aaron Diamond AIDS Research Center and The Rockefeller University, New York, New York 10016, USA
    J Virol 76:5271-3. 2002
    ..The rapid clearance and degradation of exogenously infused virions may pose a major obstacle for gene therapy with viral vectors, unless strategies to overcome the rapid in vivo elimination of these particles are developed...
  55. ncbi request reprint Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy
    Narendra M Dixit
    Theoretical Biology and Biophysics, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, USA
    Antivir Ther 9:237-46. 2004
    ....
  56. ncbi request reprint Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics
    Richard Y Kao
    Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Chem Biol 11:1293-9. 2004
    ....
  57. pmc Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes
    Xia Jin
    Infectious Disease Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, USA
    J Virol 76:12603-10. 2002
    ..05). The data are consistent with the hypothesis that higher levels of virus-specific CTL contribute to protection against HIV disease progression in infected individuals with B*35-PY, but not in those with B*35-Px...
  58. pmc Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection
    Michele Di Mascio
    Theoretical Division, Los Alamos National Laboratory, New Mexico, USA
    J Virol 78:10566-73. 2004
    ..Finally, in PHI patients the VL set point was a significant predictor of blip frequency during treatment...
  59. ncbi request reprint Modeling deuterated glucose labeling of T-lymphocytes
    Ruy M Ribeiro
    Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, MS K710, Los Alamos, New Mexico 87545, USA
    Bull Math Biol 64:385-405. 2002
    ..The use of these models in the interpretation of the experimental data will increase our knowledge of T cell dynamics in the context of HIV infection...
  60. doi request reprint The changing face of HIV in China
    Lin Lu
    Yunnan Center for Disease Control and Prevention, Yunnan, People s Republic of China
    Nature 455:609-11. 2008
    ..HIV has advanced from high-risk groups such as intravenous drug users to some in the general population, according to comprehensive new data from the south of China. What needs to be done to halt its spread?..
  61. pmc A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses
    Ming wei Chen
    Genomics Research Center, Academia Sinica, Taipei 115, Taiwan
    Proc Natl Acad Sci U S A 105:13538-43. 2008
    ..2) or significant (clade 2.1) protection from H5N1 virus challenges. We conclude that this vaccine, based on a consensus HA, could induce broad protection against divergent H5N1 influenza viruses and thus warrants further study...
  62. ncbi request reprint Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy
    Michele Di Mascio
    Theoretical Division, Los Alamos National Laboratory, 1 Los Alamos Lab, Los Alamos, NM 87545 0001, USA
    Math Biosci 188:47-62. 2004
    ....
  63. ncbi request reprint In vivo replication kinetics of a nef-deleted strain of HIV-1
    Suzanne M Crowe
    AIDS 19:842-3. 2005
  64. pmc In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted?
    Ruy M Ribeiro
    Theoretical Division, Los Alamos National Laboratory, NM 87545, USA
    Proc Natl Acad Sci U S A 99:15572-7. 2002
    ..Our results also explain why telomeres shorten in CD8(+) cells, but not in CD4(+) cells of HIV-1-infected patients, compared with age-matched controls...
  65. pmc Viral blip dynamics during highly active antiretroviral therapy
    Michele Di Mascio
    Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
    J Virol 77:12165-72. 2003
    ....
  66. pmc Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4
    Theresa L Y Chang
    Osel, Inc, 1800 Wyatt Drive, Suite 14, Santa Clara, CA 95054, USA
    Proc Natl Acad Sci U S A 100:11672-7. 2003
    ..This represents an important first step toward the development of engineered commensal bacteria within the vaginal microflora to inhibit heterosexual transmission of HIV...
  67. pmc Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication
    Diane M Janowicz
    Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN 46202, USA
    J Infect Dis 195:1443-51. 2007
    ..Thus, prompt treatment of chancroid may abrogate increases in viral replication associated with natural disease...
  68. pmc Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China
    Yong Zhang
    Yunnan Center for Disease Control and Prevention, Kunming, Yunnan, People s Republic of China
    PLoS Med 3:e443. 2006
    ..However, the molecular epidemiology of HIV-1 in Yunnan has not been fully characterized...
  69. ncbi request reprint SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
    Patrick C Y Woo
    Department of Microbiology, The University of Hong Kong, Room 423, University Pathology Building, Queen Mary Hospital, Hong Kong
    Vaccine 23:4959-68. 2005
    ..The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems...
  70. ncbi request reprint Duration of an intermittent episode of viremia
    Michele Di Mascio
    Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    Bull Math Biol 67:885-900. 2005
    ..e., a so-called transient episode of viremia. By analyzing time series of blips from a large number of patients, we conclude that transient episodes of viremia exist and that on average they extend for a period of about 3 weeks...
  71. ncbi request reprint Recognition of bacterial glycosphingolipids by natural killer T cells
    Yuki Kinjo
    Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, San Diego, 10355 Science Center Drive, San Diego, California 92121, USA
    Nature 434:520-5. 2005
    ....
  72. ncbi request reprint Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques
    Rob J de Boer
    Theoretical Biology, Utrecht University, Utrecht, The Netherlands
    J Immunol 170:2479-87. 2003
    ..Because the viral load and the CD4 T cell count are negatively correlated we cannot determine which of the two plays the most important role in this generalized immune activation...
  73. pmc Estimating average cellular turnover from 5-bromo-2'-deoxyuridine (BrdU) measurements
    Rob J de Boer
    Department of Theoretical Biology, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
    Proc Biol Sci 270:849-58. 2003
    ..2% day(-1) in SIV-infected monkeys. Thus, we show that one can use BrdU data from a possibly heterogeneous population of cells to estimate the average turnover rate of that population in a robust manner...